Evotec AG - Product Pipeline Review - 2016 Summary Global Markets Direct's, ‘Evotec AG - Product Pipeline Review - 2016', provides an overview of the Evotec AG's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Evotec AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Evotec AG - The report provides overview of Evotec AG including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Evotec AG's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Evotec AG's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to Buy - Evaluate Evotec AG's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Evotec AG - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Evotec AG's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Content
Table of Contents 2 List of Tables 6 List of Figures 6 Evotec AG Snapshot 7 Evotec AG Overview 7 Key Information 7 Key Facts 7 Evotec AG - Research and Development Overview 8 Key Therapeutic Areas 8 Evotec AG - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 Pipeline Products - Partnered Products 13 Partnered Products/Combination Treatment Modalities 14 Pipeline Products - Out-Licensed Products 15 Out-Licensed Products/Combination Treatment Modalities 16 Evotec AG - Pipeline Products Glance 17 Evotec AG - Clinical Stage Pipeline Products 17 Phase II Products/Combination Treatment Modalities 17 Phase I Products/Combination Treatment Modalities 18 Evotec AG - Early Stage Pipeline Products 19 Preclinical Products/Combination Treatment Modalities 19 Discovery Products/Combination Treatment Modalities 20 Evotec AG - Drug Profiles 21 EVT-201 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 EVT-401 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Drug to Inhibit KDM for Oncology 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Drugs for Endometriosis 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 EVT-070 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 EVT-601 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 EVT-701 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 EVT-801 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecules for Pain 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Cell Therapy for Type 1 Diabetes and Type 2 Diabetes 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Drug for Kidney Diseases 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Drugs for Alzheimer's Disease 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Drugs for Multiple Sclerosis 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Drugs for Tissue Fibrosis 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Drugs to Inhibit FGFR3 for Bladder Cancer 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Drugs to Target EEM for Type 1 Diabetes and Type 2 Diabetes 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Induced Pluripotent Stem Cells for Amyotrophic Lateral Sclerosis 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecules for Chronic Kidney Disease 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Small Molecules for Dysferlinopathies 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small Molecules for Glioblastoma Multiforme 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Small Molecules for Huntington Disease 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Small Molecules for Inflammation 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Small Molecules for Multiple Sclerosis 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Small Molecules for Neurodegenerative diseases 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Small Molecules for Solid Tumor 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Small Molecules to Agonize Orexin Receptor 2 for Nacrcolepsy 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Small Molecules to Inhibit PGB for Bacterial Infections 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Evotec AG - Pipeline Analysis 50 Evotec AG - Pipeline Products by Target 50 Evotec AG - Pipeline Products by Route of Administration 51 Evotec AG - Pipeline Products by Molecule Type 52 Evotec AG - Pipeline Products by Mechanism of Action 53 Evotec AG - Recent Pipeline Updates 54 Evotec AG - Dormant Projects 55 Evotec AG - Discontinued Pipeline Products 56 Discontinued Pipeline Product Profiles 56 EVT-301 56 sembragiline 56 ocaperidone 56 REN-1654 56 REN-213 56 REN-850 56 Evotec AG - Locations And Subsidiaries 57 Head Office 57 Other Locations & Subsidiaries 57 Appendix 59 Methodology 59 Coverage 59 Secondary Research 59 Primary Research 59 Expert Panel Validation 59 Contact Us 59 Disclaimer 60
List of Tables
Evotec AG, Key Information 7 Evotec AG, Key Facts 7 Evotec AG - Pipeline by Indication, 2016 9 Evotec AG - Pipeline by Stage of Development, 2016 11 Evotec AG - Monotherapy Products in Pipeline, 2016 12 Evotec AG - Partnered Products in Pipeline, 2016 13 Evotec AG - Partnered Products/ Combination Treatment Modalities, 2016 14 Evotec AG - Out-Licensed Products in Pipeline, 2016 15 Evotec AG - Out-Licensed Products/ Combination Treatment Modalities, 2016 16 Evotec AG - Phase II, 2016 17 Evotec AG - Phase I, 2016 18 Evotec AG - Preclinical, 2016 19 Evotec AG - Discovery, 2016 20 Evotec AG - Pipeline by Target, 2016 50 Evotec AG - Pipeline by Route of Administration, 2016 51 Evotec AG - Pipeline by Molecule Type, 2016 52 Evotec AG - Pipeline Products by Mechanism of Action, 2016 53 Evotec AG - Recent Pipeline Updates, 2016 54 Evotec AG - Dormant Developmental Projects,2016 55 Evotec AG - Discontinued Pipeline Products, 2016 56 Evotec AG, Subsidiaries 57
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.